As our planet's population continues to grow and age, finding new and innovative healthcare solutions will be paramount. However, it takes a lot of work and money in order to get a new drug to market. From beginning research to running clinical trials, creating new therapies is a daunting task. This intensive process is one of the major reasons why healthcare costs have eclipsed the rate of inflation over the last 20 years. In order to save on expenses, a variety of biotech and drug manufacturers have started outsourcing various steps in the process to a group of independent lab firms. These contract research organizations (CROs) are finally beginning to attract investor attention and could be a great way to play healthcare's growth.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Big Money in Outsourcing
With more than $106.9 billion worth of annual branded drugs sales coming off patent, from now until 2020, Big Pharma needs to reinvent its pipeline. This is driving an average projected 3.6% to 8% growth in R&D budgets among drug makers and biotechs. However, at the same time, prices for creating these therapies has surged exponentially. New high tech sequencing, further regulation from the FDA and "difficult to crack" diseases have all pushed development costs higher and higher. In order to combat these expenditures, many drug makers have started to outsource steps along the way. (For related reading, see How To Do Qualitative Analysis On Biotech Companies.)

And there's big money for those firms that run all of these clinical trials. According to data from IMS Health, outsourcing drug trials and basic lab work is currently a $60 billion market opportunity. More than 27% of the largest drug makers expect to outsource trials in 2012, while almost half of the smallest biotech companies expect to do likewise. With expanding R&D budgets and rising costs, the CROs are in a sweet spot to profit.

Analysts at Morningstar (Nasdaq:MORN) expect growth in the CRO industry to continue accelerating throughout 2012. The industry has started to adopt a strategic partnership model that will ultimately benefit the sector long-term. This has allowed major drug makers to pair up with leading CROs as long-term partners in research and development. In addition, private-equity buyers have shown a certain enthusiasm for CROs of late and started to gobble them up at premiums. Private equity firms, the Carlyle Group and Hellman & Friedman, recently agreed to pay $3.9 billion in cash to buy Pharmaceutical Product Development.

Running Your Own Trials
For investors, the contract research firms could be a great way to play healthcare's long term picture. While some broad-based biotech ETFs, like the Market Vectors Biotech ETF (ARCA:BBH), do contain some exposure to CROs such as Charles River Laboratories (NYSE:CRL), that exposure is limited. The best way to play is through individual holdings.

Partnering with pharma giant Pfizer (NYSE:PFE), ICON plc (Nasdaq:ICLR) is a great example in the sector. The company has the global scale needed to succeed in the ever-increasing complex regulatory environment and the firm expects to grow revenues 9% annually. In addition, the firm has a healthy cash balance and due to where it is domiciled (Ireland), the company's shares are trading at a discount. Similarly, CRO PAREXEL (Nasdaq:PRXL) has also partnered with Pfizer.

Chinese CRO WuXi PharmaTech (NYSE:WX) has seen its revenues rise as the firm has started expanding its manufacturing operations throughout the R&D process. The CRO is responsible for manufacturing hepatitis C therapy Incivek for Vertex (Nasdaq:VRTX) and Johnson & Johnson (NYSE:JNJ), and will continue to benefit from China's low wages and drug developers' need to cut costs. (For related reading, see A Primer On The Biotech Sector.)

Bottom Line
As drug makers need to beef up their pipelines in world of rising costs, the contract research sector will continue to see its stars shine. The previously mentioned firms are great ways to play the need for outsourcing and cost cutting.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    Top 3 Japanese Bond ETFs

    Learn about the top three exchange-traded funds (ETFs) that invest in sovereign and corporate bonds issued by developed countries, including Japan.
  2. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  3. Savings

    Become Your Own Financial Advisor

    If you have some financial know-how, you don’t have to hire someone to advise you on investments. This tutorial will help you set goals – and get started.
  4. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  5. Investing Basics

    6 Reasons Hedge Funds Underperform

    Understand the hedge fund industry and why it has grown exponentially since 1995. Learn about the top six reasons why the industry underperforms.
  6. Mutual Funds & ETFs

    Top Three Transportation ETFs

    These three transportation funds attract the majority of sector volume.
  7. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  8. Investing Basics

    Tops Tips for Trading ETFs

    A look at two different trading strategies for ETFs - one for investors and the other for active traders.
  9. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  10. Investing

    5 Recession Resistant Industries

    No companies are completely recession proof, but some industries perform better in a weak economy than others.
  1. Can mutual funds invest in IPOs?

    Mutual funds can invest in initial public offerings (IPOS). However, most mutual funds have bylaws that prevent them from ... Read Full Answer >>
  2. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. Does index trading increase market vulnerability?

    The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>
  6. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!